Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
Schim van der Loeff, Maarten F; Martinez-Steele, Euridice; Corrah, Tumani; Awasana, Akum A; van der Sande, Mariane; Sarge-Njie, Ramu; McConkey, Samuel; Jaye, Assan; Whittle, Hilton
MRC Laboratories, The Gambia.
Received 25 September, 2007
Accepted 18 October, 2007
In their criticism, Winter et al.  imply that, for the purpose of our previous study , highly-active antiretroviral therapy (HAART) was withheld, even though it was obtainable in Europe at the time. They stated that it is the duty of researchers to offer the best treatment to their patients; they believe ‘there is only one world’ and this principle should be applied to all research patients in all countries.
Like all researchers in resource limited countries, we battle with this dilemma. Like many, we strive to provide better than the best locally available treatment, but do not of necessity shun research if optimal therapy is unavailable. This proved to be the case at the time of our study in The Gambia and of other longitudinal studies of HIV in Africa . Despite repeated efforts, we could not obtain funds for HAART because research agencies were unwilling, and the Government unable, to commit to the long-term provision of drugs that were very expensive. The situation changed in 2004 when the Gambian Government and Medical Research Council obtained a grant from the Global Fund to provide antiretroviral treatment for HIV infection. At no time was this, or any other proven treatment, denied to our research patients when it was available.
Our stance may be subject to criticism and misinterpretation, but we argue, along with many others, that medical research in poor countries is a necessity and may be envisaged even if the treatment on offer does not meet the best international standards [4,5]. Thus, studies of hepatocellular carcinoma, which is very common in The Gambia, continue despite a lack of resources for the treatment of chronic hepatitis B or C carriers or facilities for liver transplantation. However, our research patients benefit from better care and treatment and all studies are subject to rigorous scientific scrutiny before approval both by local and international ethics committees.
This article has been cited 1 time(s).
© 2008 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at AIDS.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics